RS62769B1 - Postupci za lečenje hiperlipidemije inhibitorom angptl8 i inhibitorom angptl3 - Google Patents

Postupci za lečenje hiperlipidemije inhibitorom angptl8 i inhibitorom angptl3

Info

Publication number
RS62769B1
RS62769B1 RS20211568A RSP20211568A RS62769B1 RS 62769 B1 RS62769 B1 RS 62769B1 RS 20211568 A RS20211568 A RS 20211568A RS P20211568 A RSP20211568 A RS P20211568A RS 62769 B1 RS62769 B1 RS 62769B1
Authority
RS
Serbia
Prior art keywords
inhibitor
methods
angptl8
angptl3
treating hyperlipidemia
Prior art date
Application number
RS20211568A
Other languages
English (en)
Inventor
Jesper Gromada
Viktoria Gusarova
Andrew J Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of RS62769B1 publication Critical patent/RS62769B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507Comprising a combination of two or more separate antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
RS20211568A 2016-04-08 2017-04-07 Postupci za lečenje hiperlipidemije inhibitorom angptl8 i inhibitorom angptl3 RS62769B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662319980P 2016-04-08 2016-04-08
US201762453110P 2017-02-01 2017-02-01
PCT/US2017/026679 WO2017177181A1 (en) 2016-04-08 2017-04-07 Methods for treating hyperlipidemia with an angptl8 inhibitor and an angptl3 inhibitor
EP17719107.9A EP3439689B1 (en) 2016-04-08 2017-04-07 Methods for treating hyperlipidemia with an angptl8 inhibitor and an angptl3 inhibitor

Publications (1)

Publication Number Publication Date
RS62769B1 true RS62769B1 (sr) 2022-01-31

Family

ID=58610026

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20211568A RS62769B1 (sr) 2016-04-08 2017-04-07 Postupci za lečenje hiperlipidemije inhibitorom angptl8 i inhibitorom angptl3

Country Status (21)

Country Link
US (3) US20170291937A1 (sr)
EP (1) EP3439689B1 (sr)
JP (1) JP6964090B2 (sr)
KR (1) KR20180132843A (sr)
CN (1) CN109789194B (sr)
AU (1) AU2017248356A1 (sr)
CA (1) CA3020175A1 (sr)
CY (1) CY1124902T1 (sr)
ES (1) ES2896107T3 (sr)
HR (1) HRP20212028T1 (sr)
HU (1) HUE056878T2 (sr)
IL (1) IL262130A (sr)
LT (1) LT3439689T (sr)
MD (1) MD3439689T2 (sr)
MX (1) MX2018012221A (sr)
PL (1) PL3439689T3 (sr)
PT (1) PT3439689T (sr)
RS (1) RS62769B1 (sr)
SI (1) SI3439689T1 (sr)
WO (1) WO2017177181A1 (sr)
ZA (1) ZA201806264B (sr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR087329A1 (es) 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗angptl8抗體及其用途
JP7133551B2 (ja) 2016-11-17 2022-09-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗angptl8抗体を用いて肥満を処置する方法
AU2018366122A1 (en) 2017-11-10 2020-04-23 Ngm Biopharmaceuticals, Inc. ANGPTL8-binding agents and methods of use thereof
WO2019126194A1 (en) 2017-12-18 2019-06-27 Regeneron Pharmaceuticals, Inc. Angptl8 assay and uses thereof
CN113166760A (zh) * 2018-11-23 2021-07-23 赛诺菲 用于抑制angptl8的新型rna组合物和方法
TWI747098B (zh) * 2018-12-21 2021-11-21 美商美國禮來大藥廠 抗angptl3/8複合物抗體及其使用方法
CN112062845B (zh) * 2019-06-10 2022-09-02 山东博安生物技术股份有限公司 Angptl3结合片段及其用途
CN110596399B (zh) * 2019-08-29 2022-07-22 首都医科大学附属北京安贞医院 检测血管生成素样蛋白8含量的物质的应用
CN110613847B (zh) * 2019-10-23 2022-02-11 北京市心肺血管疾病研究所 一种抑制血管生成素样蛋白8的物质的应用
CN110694068A (zh) * 2019-11-06 2020-01-17 北京市心肺血管疾病研究所 一种抑制血管生成素样蛋白8的物质的应用
CN110694067A (zh) * 2019-11-06 2020-01-17 首都医科大学附属北京安贞医院 一种抑制血管生成素样蛋白8的物质的应用
CN110938144B (zh) * 2019-11-27 2022-07-26 复旦大学附属儿科医院 一种抗angptl3单克隆抗体及其在制备治疗肾病综合征药物中的用途
CN111135303A (zh) * 2020-01-17 2020-05-12 北京市心肺血管疾病研究所 一种抑制血管生成素样蛋白8的物质的应用
JP2023510787A (ja) * 2020-01-22 2023-03-15 江蘇恒瑞医薬股▲ふん▼有限公司 抗angptl3抗体及びその応用
US20230193271A1 (en) * 2021-12-22 2023-06-22 Regeneron Pharmaceuticals, Inc. Treatment Of Kidney Diseases With Angiopoietin Like 3 (ANGPTL3) Inhibitors
CN114671943B (zh) * 2022-04-29 2023-05-05 四川大学 一种鱼类摄食调控蛋白的制备和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
RS52643B (sr) 2006-06-02 2013-06-28 Regeneron Pharmaceuticals Inc. Antitela visokog afiniteta prema humanom il-6 receptoru
WO2012168491A1 (en) 2011-06-10 2012-12-13 Novartis Ag Pharmaceutical formulations of pcsk9 antagonists
AR087329A1 (es) * 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
EP3822287A1 (en) * 2014-10-03 2021-05-19 NGM Biopharmaceuticals, Inc. Angptl8 polypeptide and its use for treatment of conditions associated with elevated triglycerides
TW201713690A (zh) * 2015-08-07 2017-04-16 再生元醫藥公司 抗angptl8抗體及其用途

Also Published As

Publication number Publication date
ZA201806264B (en) 2019-07-31
EP3439689A1 (en) 2019-02-13
WO2017177181A1 (en) 2017-10-12
LT3439689T (lt) 2021-11-10
MX2018012221A (es) 2019-02-13
CY1124902T1 (el) 2023-01-05
CN109789194A (zh) 2019-05-21
US20170291937A1 (en) 2017-10-12
JP6964090B2 (ja) 2021-11-10
MD3439689T2 (ro) 2021-12-31
AU2017248356A1 (en) 2018-10-25
ES2896107T3 (es) 2022-02-23
PL3439689T3 (pl) 2022-01-31
SI3439689T1 (sl) 2021-12-31
JP2019513751A (ja) 2019-05-30
IL262130A (en) 2018-11-29
KR20180132843A (ko) 2018-12-12
US20200377583A1 (en) 2020-12-03
HRP20212028T1 (hr) 2022-04-01
HUE056878T2 (hu) 2022-03-28
US20220127348A1 (en) 2022-04-28
CA3020175A1 (en) 2017-10-12
EP3439689B1 (en) 2021-10-13
PT3439689T (pt) 2021-11-04
CN109789194B (zh) 2022-08-02

Similar Documents

Publication Publication Date Title
IL262130A (en) Methods for treating excess fat in the blood using angptl8 inhibitor and angptl3 inhibitor
ME03759B (me) Inhibitori bromodomena
EP3472362C0 (en) PAPD7 AND PAPD5 INHIBITORS TO TREAT HEPATITIS B INFECTION
HK1252937A1 (zh) 用於治療抑鬱症的方法和試劑盒
HUE056652T2 (hu) Bevonóberendezés és annak mûködési eljárása
EP3399922A4 (en) METHOD AND DEVICES FOR TREATMENT OF STROKE
IL259795A (en) Methods and compositions for treating diseases associated with serpinc1
HK1249469A1 (zh) 用RORγ抑制劑治療癌症的方法
PT3170949T (pt) Revestimento de superfícies e grampo para o referido revestimento
GB201605126D0 (en) Inhibitors and their uses
PT3448516T (pt) Aparelhos de fototerapia
IL263330B (en) Device and method for coordinating muzzle sight
HK1252172A1 (zh) 用於使用stat3途徑抑制劑和激酶抑制劑治療癌症的方法
GB201601942D0 (en) Cache and method
GB201501093D0 (en) Auto-focussing method and device
IL254003A0 (en) Improved Hemorrhoid Treatment and Reloading Device
IL273155A (en) Methods for treating depression and major depressive disorders
GB201702010D0 (en) Oven tray and method
ZA202000407B (en) Device and method for treating must
PL3325985T3 (pl) Urządzenie do dozymetrii elektromagnetycznej i powiązany sposób
PL3059631T3 (pl) Urządzenia i sposoby dostarczania światła
IL264014B (en) Device and method for orientation
IL247379A0 (en) A method for treating depression and major depressive disorder
ZA201807614B (en) Bromodomain inhibitors
GB2548916B (en) Muzzle and headcollar